What is Apellis Pharmace's earnings per share (EPS)?

Apellis Pharmace (APLS) reported diluted earnings per share of $0.20 for fiscal year 2025. This represents a 112.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Apellis Pharmace Financials

APLS

FY2025 annual

Revenue $1.0B +28.5% YoY

Net Income $22.4M +111.3% YoY

EPS (Diluted) $0.20 +112.5% YoY

Free Cash Flow $45.0M +151.0% YoY

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported May 7, 2026 Currency USD FYE December

Apellis Pharmace (APLS) reported $1.0B in revenue for fiscal year 2025, up 28.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI APLS FY2025 2026-08-29

Commercial scale has finally reached breakeven, but working-capital growth is absorbing more of the balance sheet.

The key shift is not merely profitability: revenue reached $1.0B in FY2025 as operating cash flow turned positive, reversing the prior year's outflow. Net income also moved from -$197.9M to $22.4M, so earnings quality improved alongside cash conversion rather than relying on an accounting-only rebound. This matters because the business is now financing less of its reported activity through external cash sources than it did during the loss period.

Operating margin improved from -130.4% in FY2023 to 5.5% in FY2025, a shift from losses that overwhelmed revenue to modest operating profitability. SG&A still rose to $550M in FY2025, so the cleaner explanation is scale absorbing a large operating-cost base—not evidence of pricing or product-mix gains, which these tables cannot isolate.

Current ratio fell from 4.3x in FY2022 to 3.1x in FY2025, indicating a thinner liquidity cushion even as the ratio remains above one. Current liabilities reached $323.6M while accounts receivable reached $366.2M, making working capital a larger balance-sheet commitment than the cash result alone suggests. Debt-to-equity was 1.9x in FY2025 versus 0.5x in FY2022, so improving income has not translated into a uniformly more conservative financing posture.

Financial Health Signals

Financial Health Score 43/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Apellis Pharmace's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Apellis Pharmace has an operating margin of 5.5%, meaning the company retains $6 of operating profit per $100 of revenue. This below-average margin results in a low score of 19/100, suggesting thin profitability after operating expenses. This is up from -21.1% the prior year.

Growth

Apellis Pharmace's revenue surged 28.5% year-over-year to $1.0B, reflecting rapid business expansion. This strong growth earns a score of 96/100.

Leverage

Apellis Pharmace has a moderate D/E ratio of 1.90. This balance of debt and equity financing earns a leverage score of 32/100.

Liquidity

With a current ratio of 3.14, Apellis Pharmace holds $3.14 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 78/100.

Cash Flow

Apellis Pharmace's free cash flow margin of 4.5% results in a low score of 10/100. Capital expenditures of $313K absorb a large share of operating cash flow.

Returns

Apellis Pharmace generates a 6.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 22/100. This is up from -86.6% the prior year.

Altman Z-Score Grey Zone

2.42

Apellis Pharmace scores 2.42, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($5.3B) relative to total liabilities ($705.1M). This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

5/7

Apellis Pharmace passes 5 of 7 computable financial strength tests (2 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Cash-Backed

2.02x

For every $1 of reported earnings, Apellis Pharmace generates $2.02 in operating cash flow ($45.3M OCF vs $22.4M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage At Risk

1.25x

Apellis Pharmace earns $1.25 in operating income for every $1 of interest expense ($55.4M vs $44.3M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.0B

YoY+28.5%

5Y CAGR+32.0%

Apellis Pharmace generated $1.0B in revenue in fiscal year 2025. This represents an increase of 28.5% from the prior year.

EBITDA

$57.0M

YoY+134.9%

Apellis Pharmace's EBITDA was $57.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 134.9% from the prior year.

Net Income

$22.4M

YoY+111.3%

Apellis Pharmace reported $22.4M in net income in fiscal year 2025. This represents an increase of 111.3% from the prior year.

EPS (Diluted)

$0.20

YoY+112.5%

Apellis Pharmace earned $0.20 per diluted share (EPS) in fiscal year 2025. This represents an increase of 112.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$45.0M

YoY+151.0%

Apellis Pharmace generated $45.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 151.0% from the prior year.

Cash & Debt

$466.2M

YoY+13.4%

5Y CAGR-3.8%

10Y CAGR+29.2%

Apellis Pharmace held $466.2M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

128M

YoY+1.8%

5Y CAGR+9.7%

Apellis Pharmace had 128M shares outstanding in fiscal year 2025. This represents an increase of 1.8% from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Operating Margin

5.5%

YoY+26.6pp

5Y CAGR+90.8pp

Apellis Pharmace's operating margin was 5.5% in fiscal year 2025, reflecting core business profitability. This is up 26.6 percentage points from the prior year.

Net Margin

2.2%

YoY+27.5pp

Apellis Pharmace's net profit margin was 2.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 27.5 percentage points from the prior year.

Return on Equity

6.0%

YoY+92.6pp

5Y CAGR+174.7pp

10Y CAGR+139.0pp

Apellis Pharmace's ROE was 6.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 92.6 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

$295.9M

YoY-9.7%

5Y CAGR-0.3%

10Y CAGR+35.9%

Apellis Pharmace invested $295.9M in research and development in fiscal year 2025. This represents a decrease of 9.7% from the prior year.

Capital Expenditures

$313K

YoY-22.3%

5Y CAGR-43.5%

Apellis Pharmace invested $313K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 22.3% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

APLS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

APLS quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15
Revenue	$1.1B	$1.0B+28.5%	$781.4M+97.0%	$396.6M+425.8%	$75.4M+13.3%	$66.6M-73.4%	$250.6M	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$286.4M	$295.9M-9.7%	$327.6M-7.6%	$354.4M-8.5%	$387.2M+12.0%	$345.9M+15.3%	$299.9M+35.7%	$221.0M+109.9%	$105.3M+161.2%	$40.3M+75.4%	$23.0M+67.4%	$13.7M
SG&A Expenses	$545.2M	$550.3M+9.8%	$501.1M0.0%	$500.8M+80.7%	$277.2M+56.8%	$176.8M+26.8%	$139.4M+107.9%	$67.0M+196.2%	$22.6M+116.4%	$10.5M+143.1%	$4.3M-32.3%	$6.4M
Operating Income	$165.2M	$55.4M+133.6%	-$165.0M+68.1%	-$517.1M+13.0%	-$594.6M-10.9%	-$536.3M-150.9%	-$213.7M+25.8%	-$288.0M-125.1%	-$127.9M-152.0%	-$50.8M-86.1%	-$27.3M+41.4%	-$46.6M
Interest Expense	$43.6M	$44.3M+9.7%	$40.4M+36.5%	$29.6M+418.3%	$5.7M-52.6%	$12.1M+236.3%	$3.6M	N/A	N/A	N/A	N/A	N/A
Income Tax	$1.9M	$1.7M+48.2%	$1.2M-45.5%	$2.1M+218.7%	$669K+90.1%	$352K-80.9%	$1.8M	N/A	N/A	N/A	N/A	N/A
Net Income	$133.3M	$22.4M+111.3%	-$197.9M+62.6%	-$528.6M+18.9%	-$652.2M+12.6%	-$746.4M-116.4%	-$344.9M-13.2%	-$304.7M-139.0%	-$127.5M-150.0%	-$51.0M-88.0%	-$27.1M+41.7%	-$46.5M
EPS (Diluted)	$1.04	$0.20+112.5%	-$1.60+64.0%	-$4.45+27.6%	-$6.15+30.4%	-$8.84-92.6%	-$4.59	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$268.3M+34.2%	$199.9M-56.4%	$458.6M+156.9%	$178.5M+7.0%	$166.8M-21.5%	$212.5M+8.0%	$196.8M-1.4%	$199.7M
R&D Expenses	$77.0M+3.7%	$74.2M+8.9%	$68.2M+1.7%	$67.0M-22.5%	$86.4M+13.2%	$76.4M-13.8%	$88.6M+13.6%	$77.9M
SG&A Expenses	$124.3M-15.5%	$147.1M+3.1%	$142.7M+8.8%	$131.1M+1.4%	$129.3M+6.5%	$121.5M-0.4%	$122.0M-4.8%	$128.1M
Operating Income	$26.5M+151.8%	-$51.1M-122.9%	$223.2M+770.5%	-$33.3M+60.1%	-$83.3M-218.5%	-$26.2M+44.7%	-$47.3M-60.6%	-$29.4M
Interest Expense	$10.3M-4.9%	$10.8M-3.8%	$11.3M+1.1%	$11.2M+0.9%	$11.0M-4.2%	$11.5M-8.0%	$12.5M+33.9%	$9.4M
Income Tax	$496K+58.5%	$313K-48.0%	$602K+29.2%	$466K+36.7%	$341K+19.2%	$286K-51.7%	$592K+419.3%	$114K
Net Income	$18.7M+131.6%	-$59.0M-127.3%	$215.7M+611.8%	-$42.2M+54.3%	-$92.2M-153.7%	-$36.4M+36.7%	-$57.4M-52.5%	-$37.7M
EPS (Diluted)	$0.15+133.3%	-$0.45-126.9%	$1.67+606.1%	-$0.33+55.4%	-$0.74-155.2%	-$0.29+37.0%	-$0.46-53.3%	-$0.30

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

APLS Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

APLS quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15
Total Assets	$1.1B+21.5%	$885.1M+12.2%	$788.7M+3.8%	$760.2M-13.8%	$881.8M-8.2%	$960.6M+146.8%	$389.2M+91.2%	$203.5M+11.8%	$182.1M+563.9%	$27.4M	N/A
Current Assets	$1.0B+28.6%	$789.0M+3.0%	$766.3M+6.5%	$719.5M-12.7%	$824.0M-10.2%	$917.2M+145.8%	$373.1M+84.3%	$202.4M+11.2%	$182.0M+565.0%	$27.4M	N/A
Cash & Equivalents	$466.2M+13.4%	$411.3M+17.1%	$351.2M-36.4%	$551.8M-13.8%	$640.2M+13.2%	$565.8M+60.7%	$352.0M+99.7%	$176.3M+0.4%	$175.6M+606.4%	$24.9M-30.9%	$36.0M
Inventory	$142.6M+75.1%	$81.4M-44.4%	$146.4M+70.8%	$85.7M+426.3%	$16.3M	$0	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$366.2M+38.2%	$264.9M+28.3%	$206.4M+2571.7%	$7.7M-23.5%	$10.1M	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$705.1M+7.4%	$656.5M+10.5%	$594.2M+0.7%	$590.3M-13.6%	$683.1M-9.6%	$756.0M+113.0%	$355.0M+734.1%	$42.6M+28.2%	$33.2M+812.0%	$3.6M	N/A
Current Liabilities	$323.6M+74.4%	$185.5M-25.1%	$247.6M+47.7%	$167.6M+27.1%	$131.8M+2.7%	$128.3M+95.2%	$65.8M+286.2%	$17.0M+159.8%	$6.6M+80.1%	$3.6M	N/A
Long-Term Debt	N/A	N/A	$93.0M+0.3%	$92.7M	N/A	N/A	N/A	N/A	$27.0M	N/A	N/A
Total Equity	$370.1M+62.0%	$228.5M+17.5%	$194.5M+14.5%	$169.9M-14.5%	$198.7M-2.9%	$204.6M+497.6%	$34.2M-78.7%	$161.0M+8.1%	$148.9M+526.0%	$23.8M-32.0%	$35.0M
Retained Earnings	-$3.0B+0.7%	-$3.0B-7.0%	-$2.8B-22.9%	-$2.3B-39.4%	-$1.7B-78.8%	-$926.3M-59.3%	-$581.5M-110.1%	-$276.8M-85.4%	-$149.3M-51.9%	-$98.3M	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$1.1B+0.7%	$1.1B+1.6%	$1.1B+28.9%	$821.4M+1.7%	$807.3M-8.8%	$885.1M-1.9%	$901.9M-0.3%	$904.5M
Current Assets	$1.0B+1.3%	$1.0B+2.4%	$990.7M+31.1%	$755.6M+3.8%	$727.7M-7.8%	$789.0M-5.4%	$833.9M-3.0%	$860.0M
Cash & Equivalents	$405.2M-13.1%	$466.2M-2.7%	$479.2M+29.5%	$370.0M+3.2%	$358.4M-12.9%	$411.3M+3.6%	$396.9M+10.2%	$360.1M
Inventory	$131.4M-7.8%	$142.6M+16.1%	$122.8M+1.5%	$121.0M+46.7%	$82.5M+1.3%	$81.4M-32.8%	$121.1M-20.8%	$152.8M
Accounts Receivable	$440.3M+20.2%	$366.2M+6.0%	$345.5M+61.4%	$214.1M-9.0%	$235.2M-11.2%	$264.9M-5.0%	$279.0M-8.4%	$304.4M
Total Liabilities	$667.6M-5.3%	$705.1M+7.2%	$657.6M-1.1%	$665.1M+3.4%	$643.1M-2.0%	$656.5M-1.2%	$664.7M+3.8%	$640.2M
Current Liabilities	$283.4M-12.4%	$323.6M+15.8%	$279.5M+39.3%	$200.7M+12.5%	$178.4M-3.8%	$185.5M-3.0%	$191.3M+13.1%	$169.2M
Total Equity	$414.9M+12.1%	$370.1M-7.7%	$401.2M+156.7%	$156.3M-4.8%	$164.2M-28.1%	$228.5M-3.6%	$237.1M-10.3%	$264.3M
Retained Earnings	-$3.0B+0.6%	-$3.0B-2.0%	-$3.0B+6.8%	-$3.2B-1.3%	-$3.1B-3.0%	-$3.0B-1.2%	-$3.0B-2.0%	-$2.9B

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

APLS Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

APLS quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15
Operating Cash Flow	$37.8M	$45.3M+151.6%	-$87.9M+85.2%	-$594.7M-15.8%	-$513.7M+8.8%	-$563.1M-250.9%	-$160.5M+24.0%	-$211.1M-60.9%	-$131.2M-181.7%	-$46.6M-79.2%	-$26.0M-37.9%	-$18.9M
Capital Expenditures	N/A	$313K-22.3%	$403K-47.9%	$773K-49.3%	$1.5M+38.2%	$1.1M-79.7%	$5.4M+220.3%	$1.7M	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	$45.0M+151.0%	-$88.3M+85.2%	-$595.5M-15.6%	-$515.3M+8.7%	-$564.2M-240.1%	-$165.9M+22.0%	-$212.8M	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	-$313K+22.3%	-$403K+40.2%	-$674K-101.1%	$59.9M-75.8%	$247.6M+178.1%	-$317.0M-18623.5%	-$1.7M	N/A	N/A	N/A	N/A
Financing Cash Flow	$8.7M	$8.9M-94.0%	$149.2M-62.2%	$394.5M+7.9%	$365.7M-6.8%	$392.2M-43.3%	$692.2M+78.1%	$388.5M+194.6%	$131.9M-33.2%	$197.4M+1228.0%	$14.9M	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$61.0M-330.1%	-$14.2M-113.1%	$108.5M+2340.2%	$4.4M+108.3%	-$53.4M-375.9%	$19.4M-43.2%	$34.1M+508.9%	-$8.3M
Capital Expenditures	N/A	$108K-27.0%	$148K+202.0%	$49K+512.5%	$8K-60.0%	$20K	$0-100.0%	$90K
Free Cash Flow	N/A	-$14.3M-113.2%	$108.3M+2364.1%	$4.4M+108.2%	-$53.4M-376.2%	$19.3M-43.3%	$34.1M+504.5%	-$8.4M
Investing Cash Flow	N/A	-$108K+27.0%	-$148K-202.0%	-$49K-512.5%	-$8K+60.0%	-$20K	$0+100.0%	-$90K
Financing Cash Flow	$64K-94.9%	$1.3M+58.8%	$793K-87.9%	$6.6M+2293.4%	$274K+106.8%	-$4.0M-257.4%	$2.5M-94.0%	$42.5M

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

APLS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

APLS quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15
Operating Margin	5.5%+26.6pp	-21.1%	-130.4%	-788.4%	-805.7%	-85.3%	N/A	N/A	N/A	N/A	N/A
Net Margin	2.2%+27.5pp	-25.3%	-133.3%	-864.7%	-1121.3%	-137.6%	N/A	N/A	N/A	N/A	N/A
Return on Equity	6.0%+92.6pp	-86.6%+185.2pp	-271.8%+112.2pp	-383.9%-8.2pp	-375.7%-207.1pp	-168.6%+721.6pp	-890.2%-811.0pp	-79.2%-45.0pp	-34.3%+79.7pp	-114.0%+19.0pp	-133.0%
Return on Assets	2.1%+24.4pp	-22.4%+44.7pp	-67.0%+18.8pp	-85.8%-1.1pp	-84.6%-48.7pp	-35.9%+42.4pp	-78.3%-15.6pp	-62.6%-34.6pp	-28.0%+70.9pp	-98.9%	N/A
Current Ratio	3.14-1.1x	4.25+1.2x	3.10-1.2x	4.29-2.0x	6.25-0.9x	7.15+1.5x	5.67-6.2x	11.89-15.9x	27.77+20.3x	7.52	N/A
Debt-to-Equity	1.90-1.0x	2.87+2.4x	0.48-0.1x	0.55-2.9x	3.44-0.3x	3.70-6.7x	10.37+10.1x	0.26+0.1x	0.180.0x	0.15	N/A
FCF Margin	4.5%+15.8pp	-11.3%	-150.2%	-683.2%	-847.7%	-66.2%	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Margin	9.9%+35.4pp	-25.6%-74.3pp	48.7%+67.3pp	-18.6%+31.3pp	-50.0%-37.6pp	-12.3%+11.7pp	-24.0%-9.3pp	-14.7%
Net Margin	7.0%+36.4pp	-29.5%-76.5pp	47.0%+70.7pp	-23.6%+31.7pp	-55.3%-38.2pp	-17.1%+12.1pp	-29.2%-10.3pp	-18.9%
Return on Equity	4.5%+20.4pp	-15.9%-69.7pp	53.8%+80.7pp	-27.0%+29.2pp	-56.2%-40.3pp	-15.9%+8.3pp	-24.2%-10.0pp	-14.2%
Return on Assets	1.7%+7.2pp	-5.5%-25.9pp	20.4%+25.5pp	-5.1%+6.3pp	-11.4%-7.3pp	-4.1%+2.3pp	-6.4%-2.2pp	-4.2%
Current Ratio	3.63+0.5x	3.14-0.4x	3.54-0.2x	3.77-0.3x	4.08-0.2x	4.25-0.1x	4.36-0.7x	5.08
Debt-to-Equity	1.61-0.3x	1.90+0.3x	1.64-2.6x	4.25+0.3x	3.92+1.0x	2.87+0.1x	2.80+0.4x	2.42
FCF Margin	N/A	-7.1%-30.8pp	23.6%+21.2pp	2.5%+34.5pp	-32.0%-41.1pp	9.1%-8.2pp	17.3%+21.5pp	-4.2%

Not reported in any period shown, so not listed: Gross Margin.

Similar Companies

Scholar Rock Holding SRRK

$7.0B

Kymera Therapeutics, Inc. KYMR

$9.8B

Telix Pharmaceuticals Ltd ADR TLX

$3.8B

Immunovant Inc IMVT

$8.5B

Protagonist Ther PTGX

$9.3B

Where Apellis Pharmace Ranks

Frequently Asked Questions

What is Apellis Pharmace's annual revenue?

Apellis Pharmace (APLS) reported $1.0B in total revenue for fiscal year 2025. This represents a 28.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Apellis Pharmace's revenue growing?

Apellis Pharmace (APLS) revenue grew by 28.5% year-over-year, from $781.4M to $1.0B in fiscal year 2025.

Is Apellis Pharmace profitable?

Yes, Apellis Pharmace (APLS) reported a net income of $22.4M in fiscal year 2025, with a net profit margin of 2.2%.

What is Apellis Pharmace's EBITDA?

Apellis Pharmace (APLS) had EBITDA of $57.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Apellis Pharmace's operating margin?

Apellis Pharmace (APLS) had an operating margin of 5.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Apellis Pharmace's net profit margin?

Apellis Pharmace (APLS) had a net profit margin of 2.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Apellis Pharmace's return on equity (ROE)?

Apellis Pharmace (APLS) has a return on equity of 6.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Apellis Pharmace's free cash flow?

Apellis Pharmace (APLS) generated $45.0M in free cash flow during fiscal year 2025. This represents a 151.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Apellis Pharmace's operating cash flow?

Apellis Pharmace (APLS) generated $45.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Apellis Pharmace's total assets?

Apellis Pharmace (APLS) had $1.1B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Apellis Pharmace's capital expenditures?

Apellis Pharmace (APLS) invested $313K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Apellis Pharmace spend on research and development?

Apellis Pharmace (APLS) invested $295.9M in research and development during fiscal year 2025.

How many shares does Apellis Pharmace have outstanding?

Apellis Pharmace (APLS) had 128M shares outstanding as of fiscal year 2025.

What is Apellis Pharmace's current ratio?

Apellis Pharmace (APLS) had a current ratio of 3.14 as of fiscal year 2025, which is generally considered healthy.

What is Apellis Pharmace's debt-to-equity ratio?

Apellis Pharmace (APLS) had a debt-to-equity ratio of 1.90 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Apellis Pharmace's return on assets (ROA)?

Apellis Pharmace (APLS) had a return on assets of 2.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Apellis Pharmace's Altman Z-Score?

Apellis Pharmace (APLS) has an Altman Z-Score of 2.42, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Apellis Pharmace's Piotroski F-Score?

Apellis Pharmace (APLS) has a Piotroski F-Score of 5 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Apellis Pharmace's earnings high quality?

Apellis Pharmace (APLS) has an earnings quality ratio of 2.02x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Apellis Pharmace cover its interest payments?

Apellis Pharmace (APLS) has an interest coverage ratio of 1.25x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Apellis Pharmace?

Apellis Pharmace (APLS) scores 43 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.